Clinical trials: Adalimumab
Rheumatoid Arthritis
A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis
A total of 100 participants diagnosed with active rheumatoid arthritis were enrolled at 5 sites in Russia. Adalimumab was administered by subcutaneous injection every other week, with dose escalation to weekly dosing available…
- Trial name
- NCT01231321
- Testing
- adalimumab
- Where
- 5 sites in Russia
- Volunteers
- 100 people
- Sponsor
- Abbott
Rheumatoid Arthritis, Psoriatic Arthritis
A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
This is a five year, post-marketing observational study to follow-up patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA (adalimumab).
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- ProAct (NCT01078558)
- Volunteers
- 5,940 people
- Sponsor
- AbbVie (prior sponsor, Abbott)